{"url_path":"/sec/bixt/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-023538-index.html","accession_number":"0001493152-26-023538","cik":"0001445815","ticker":"BIXT","issuer_name":"BIOXYTRAN, INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1445815/0001493152-26-023538-index.html","primary_entity_key":"0001445815","primary_entity_name":"BIOXYTRAN, INC"},"word_count":138,"has_tables":true,"body_markdown":"**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds**\n\n \n\n**Unit\nOffering**\n\n \n\nAround\nJanuary 23, 2026, the Company proposed a private placement offering investors to purchase shares and warrants issued together as a\nunit; however, each warrant is detachable and separately exercisable to purchase one share of Common Stock. The average price was\n$0.06 per unit, less a broker (Member FINRA / SIPC) fee consisting of 8% cash commission and 8% bonus shares. The Company raised a\ntotal of $241,040 (after $20,960 cash commission) and issued 4,716,000 shares of Common Stock (after 349,333 bonus shares), as well\nas 4,366,667 5-year warrants exercisable to buy Common Stock at $0.12 per share. The net received by the Company was $0.053 per\nunit.\n\n \n\nThe funds will be used for working\ncapital purposes, predominantly for research and development and administrative expenses."}